According to a VNA reporter in Sydney, on May 28, the Royal Melbourne Hospital (RMH) announced that Australian scientists had made a breakthrough in clinical trials of a new drug capable of inhibiting tumors in patients with low-grade malignant glioma (LGG) brain cancer.
This is the first trial performed on the pioneering Brain Perioperative (BrainPOP) brain surgery platform.
LGG is a slow-growing form of brain cancer that severely affects patients, mostly young people.
The disease is associated with mutations in the IDH gene and has long been considered incurable, with limited treatment options.
In the pilot study, scientists used Safusidenib, an oral inhibitor that targets the mutated IDH1 gene. The drug was tested on tumor samples before and after treatment, with very promising results.
The research results were published in the journal Nature Medicine.
Professor Kate Drummond, Head of RMH Neurosurgery, said the trial not only opens up a new approach to treating LGG but also offers hope to a group of patients with this devastating disease.
Dr. Jim Whittle, Peter MacCallum Cancer Centre, emphasized that the study proves BrainPOP is a safe and effective platform, helping to personalize treatment and identify patients who respond best to drugs./.
Source: https://www.vietnamplus.vn/australia-thu-nghiem-thanh-cong-thuoc-moi-dieu-tri-ung-thu-nao-post1057853.vnp
Comment (0)